EXPRESSION OF MALARIA MSP-1 P42 C-TERMINAL FRAGMENT

疟疾 MSP-1 P42 C 末端片段的表达

• 批准号: 2646424
• 负责人: DAVID E CLEMENTS
• 金额: $ 10万
• 依托单位: HAWAII BIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 1998-12-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2646424
• 关键词: cell line; circumsporozoite protein; hybridomas; immunoaffinity chromatography; laboratory mouse; malaria; malaria vaccines; molecular cloning; protein purification; protein sequence; protozoal antigen; recombinant proteins; transfection; vaccine development; vector vaccine

Malaria is a tropical parasitic disease that has been a significant health threat over the years. Each year, approximately 500 million people become infected and 1 to 2 million die worldwide, with the majority of cases occurring in Africa. At this time, there is a great need to control the spread of this disease. The development of malaria vaccines has focused on the use of recombinant proteins to overcome the limitations of conventional vaccines. The goal of the proposed research is to produce a highly immunogenic recombinant subunit that can be used to formulate a vaccine against malaria. Phase I research will test the feasibility of utilizing a eukaryotic cell system to express and secrete a recombinant merozoite surface protein subunit, p42, that has a native- like confirmation. Previous attempts to express the p42 subunit resulted in low levels of expression. The expression system proposed for this research has been shown to express high levels of recombinant proteins. Use of this system for expression of malaria proteins could contribute to the development of a safe, efficacious and cost effective vaccine. PROPOSED COMMERCIAL APPLICATION Malaria poses a significant health threat. Annually, approximately 500 million people become nfected and 1 to 2 million die. Currently, there is no vaccine for malaria. The proposed research will express and secret a malaria subunit targeted for vaccine development. Successful expression of high levels of this subunit could contribute to the development of a safe, efficacious and cost effective malaria vaccine.

疟疾是一种热带寄生虫病，已成为一种严重的热带寄生虫病 多年来的健康威胁。 每年大约有 5 亿 全球有 1 至 200 万人被感染，死亡人数 大多数病例发生在非洲。 这时，有一个伟大的 需要控制这种疾病的传播。 疟疾的发展 疫苗的重点是使用重组蛋白来克服 传统疫苗的局限性。 拟议研究的目标 是产生可用于高免疫原性的重组亚基 研制疟疾疫苗。 第一阶段研究将测试 利用真核细胞系统表达和分泌的可行性 重组裂殖子表面蛋白亚基 p42，具有天然的 就像确认一样。先前尝试表达 p42 亚基的结果 处于低表达水平。 为此提出的表达系统 研究表明其可表达高水平的重组蛋白。 使用该系统表达疟疾蛋白可能有助于 开发安全、有效且具有成本效益的疫苗。 拟议的商业应用 疟疾对健康构成重大威胁。 每年约 500 100 万人被感染，1 至 200 万人死亡。 目前，有 没有疟疾疫苗。 拟议的研究将表达和 秘密开发针对疫苗开发的疟疾亚基。 成功的 该亚基的高水平表达可能有助于 开发安全、有效且具有成本效益的疟疾疫苗。